Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways

Anti-Cancer Drugs

Volumn 27, Issue 3, 2016, Pages 192-203

  Hao, Huiyao ^a   Zhang, Di ^a   Shi, Junli ^a   Wang, Yan ^a   Chen, Lei ^a   Guo, Yongze ^a   Ma, Junji ^a   Jiang, Xiaoyu ^b   Jiang, Huiqing ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autophagic cell death; Hepatic stellate cells; MTOR; Sorafenib

Indexed keywords

3 METHYLADENINE; ALOXISTATIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIFIBROTIC AGENT; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; BECLIN 1; CASPASE 3; CASPASE 8; LC3 I PROTEIN; LC3 II PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPSTATIN; PROTEIN; PROTEIN KINASE B; PROTEIN P62; S6 KINASE; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN TYROSINE KINASE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANTIFIBROTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL COUNT; CELL DEATH; CELL POPULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; METABOLISM;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL LINE; HEPATIC STELLATE CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84957933951     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000316     Document Type: Article

References (62)

1. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88:125-172.
2. Tacke F, Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol 2012; 6:67-80.
3. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134:1655-1669.
4. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011; 193:225-231.
5. Lai CL, Chien RN, Leung N.W., Chang TT, Guan R, Tai DI, et al A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
6. Ramond MJ, Poynard T, Rueff B., Mathurin P, Theodore C, Chaput J.C., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326:507-512.
7. Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 2010; 30:226-231.
8. Gordy C, He YW The crosstalk between autophagy and apoptosis: where does this lead? Protein Cell 2012; 3:17-27.
9. Klionsky DJ, Emr SD Autophagy as a regulated pathway of cellular degradation. Science 2000; 290:1717-1721.
10. Yorimitsu T, Klionsky DJ Autophagy: molecular machinery for self-eating. Cell Death Differ 2005; 12 (suppl 2):1542-1552.
11. Moreau K, Luo S, Rubinsztein DC Cytoprotective roles for autophagy. Curr Opin Cell Biol 2010; 22:206-211.
12. Shen HM, Codogno P. Autophagic cell death: Loch Ness monster or endangered species? Autophagy 2011; 7:457-465.
13. Fimia GM, Piacentini M. Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol Life Sci 2010; 67:1581-1588.
14. Hernandez-Gea V., Hilscher M, Rozenfeld R., Lim MP, Nieto N, Werner S, et al Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J Hepatol 2013; 59:98-104.
15. Hernandez-Gea V., Ghiassi-Nejad Z, Rozenfeld R., Gordon R, Fiel MI, Yue Z, et al Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 2012; 142:938-946.
16. Thoen LF, Guimaraes EL, Dolle L, Mannaerts I., Najimi M, Sokal E, et al A role for autophagy during hepatic stellate cell activation. J Hepatol 2011; 55:1353-1360.
17. Shaker ME, Ghani A, Shiha G.E., Ibrahim TM, Mehal WZ. Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochim Biophys Acta 2013; 1833:1992-2003.
18. Lyons JF, Wilhelm S, Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8:219-225.
19. Wilhelm SM, Adnane L, Newell P., Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-3140.
20. Lowinger TB, Riedl B, Dumas J., Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002; 8:2269-2278.
21. Wan PT, Garnett MJ, Roe S.M., Lee S., Niculescu-Duvaz D, Good VM, et al Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-867.
22. Wilhelm SM, Carter C, Tang L., Wilkie D, McNabola A, Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
23. Carloni S, Fabbri F, Brigliadori G., Ulivi P, Silvestrini R, Amadori D., et al. Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. Curr Cancer Drug Targets 2010; 10:422-431.
24. Yang F, Brown C, Buettner R., Hedvat M, Starr R, Scuto A., et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther 2010; 9:953-962.
25. Auclair D, Miller D, Yatsula V., Pickett W, Carter C, Chang Y., et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007; 21:439-445.
26. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W., Kowolik CM, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008; 7:3519-3526.
27. Kim S, Yazici YD, Calzada G, Wang Z.Y., Younes MN, Jasser SA, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007; 6:1785-1792.
28. Karasarides M, Chiloeches A, Hayward R., Niculescu-Duvaz D, Scanlon I, Friedlos F., et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23:6292-6298.
29. Maruwge W, D'Arcy P, Folin A, Brnjic S., Wejde J, Davis A, et al Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther 2008; 1:67-78.
30. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V., Rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46:1919-1926.
31. Mejias M, Garcia-Pras E, Tiani C., Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49:1245-1256.
32. Wang Y, Gao J, Zhang D., Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53:132-144.
33. Sodeoka M, Dodo K. Development of selective inhibitors of necrosis. Chem Rec 2010; 10:308-314.
34. Kabeya Y, Mizushima N, Ueno T., Yamamoto A, Kirisako T, Noda T., et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19:5720-5728.
35. Glick D, Barth S, Macleod KF Autophagy: cellular and molecular mechanisms. J Pathol 2010; 221:3-12.
36. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3:542-545.
37. Bjorkoy G, Lamark T, Brech A., Outzen H, Perander M, Overvatn A., et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171:603-614.
38. Yue Z. Regulation of neuronal autophagy in axon: implication of autophagy in axonal function and dysfunction/degeneration. Autophagy 2007; 3:139-141.
39. Fuest M, Willim K, MacNelly S., Fellner N, Resch GP, Blum H.E., et al. The transcription factor c-Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival. Hepatology 2012; 55:408-418.
40. Kroemer G, Galluzzi L, Vandenabeele P., Abrams J, Alnemri ES, Baehrecke E.H., et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3-11.
41. Lee YJ, Won AJ, Lee J, Jung J.H., Yoon S., Lee BM, et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 2012; 9:881-893.
42. Ullen A, Farnebo M, Thyrell L., Mahmoudi S, Kharaziha P, Lennartsson L., et al. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol 2010; 37:15-20.
43. Zauli G, Celeghini C, Melloni E., Voltan R, Ongari M, Tiribelli M., et al. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012; 97:1722-1730.
44. Shi YH, Ding ZB, Zhou J, Hui B., Shi GM, Ke AW, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stressrelated apoptosis. Autophagy 2011; 7:1159-1172.
45. Lee JI. The effect of sorafenib on hepatic stellate cells: implication of its effect on tumor microenvironment. Korean J Hepatol 2010; 16:418-419.
46. Amann T, Bataille F, Spruss T., Muhlbauer M, Gabele E, Scholmerich J., et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100:646-653.
47. Zeng KW, Fu H, Liu G.X., Wang XM. Aluminum maltolate induces primary rat astrocyte apoptosis via overactivation of the class III PI3K/Beclin 1-dependent autophagy signal. Toxicol In Vitro 2012; 26:215-220.
48. Hennenberg M, Trebicka J, Kohistani Z., Stark C, Nischalke HD, Kramer B, et al Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest 2011; 91:241-251.
49. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P., Vandenabeele P. Autophagy: for better or for worse. Cell Res 2012; 22:43-61.
50. Wirawan E, Vande Walle L, Kersse K, Cornelis S., Claerhout S, Vanoverberghe I, et al Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010; 1:e18.
51. Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012; 119:6089-6098.
52. Tai WT, Shiau CW, Chen H.L., Liu CY, Lin CS, Cheng AL, et al Mcl1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis 2013; 4:e485.
53. Liu Q, Wang X, Zhang Y., Li CJ, Hu LH, Shen X. Leukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production. Acta Pharmacol Sin 2010; 31:839-848.
54. Neef M, Ledermann M, Saegesser H., Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45:786-796.
55. Liu Q, Chen J, Wang X., Yu L, Hu LH, Shen X. Withagulatin A inhibits hepatic stellate cell viability and procollagen I production through Akt and Smad signaling pathways. Acta Pharmacol Sin 2010; 31:944-952.
56. Li J, Li X, Xu W., Wang S, Hu Z, Zhang Q., et al. Antifibrotic effects of luteolin on hepatic stellate cells and liver fibrosis by targeting AKT/mTOR/p70S6K and TGFβ/Smad signalling pathways. Liver Int 2015; 35:1222-1233.
57. Lin JC, Huang WP, Liu C.L., Lee JJ, Liu TP, Ko WC, et al Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts. Transplantation 2013; 95:791-800.
58. Chen RJ, Hung CM, Chen Y.L., Wu MD, Yuan GF, Wang YJ. Monascuspiloin induces apoptosis and autophagic cell death in human prostate cancer cells via the Akt and AMPK signaling pathways. J Agric Food Chem 2012; 60:7185-7193.
59. Xie CM, Chan WY, Yu S, Zhao J., Cheng CH. Bufalin induces autophagymediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med 2011; 51:1365-1375.
60. Parsons CJ, Takashima M, Rippe RA Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22 (suppl 1):S79-S84.
61. Lee UE, Friedman SL Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25:195-206.
62. Hong F, Chou H, Fiel M.I., Friedman SL. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci 2013; 58:257-264.